Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Crosses Above 200 Day Moving Average of $3.08

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLIGet Rating)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.08 and traded as high as $4.08. Brainstorm Cell Therapeutics shares last traded at $4.04, with a volume of 216,669 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Brainstorm Cell Therapeutics in a research note on Saturday, September 3rd. They issued a “hold” rating for the company.

Brainstorm Cell Therapeutics Stock Up 6.3 %

The company has a 50 day moving average price of $3.13 and a 200-day moving average price of $3.08. The company has a market cap of $147.40 million, a price-to-earnings ratio of -6.12 and a beta of -0.10.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Rating) last released its earnings results on Monday, August 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.04). On average, analysts forecast that Brainstorm Cell Therapeutics Inc. will post -0.68 EPS for the current fiscal year.

Institutional Trading of Brainstorm Cell Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Abner Herrman & Brock LLC boosted its holdings in shares of Brainstorm Cell Therapeutics by 13.7% during the 1st quarter. Abner Herrman & Brock LLC now owns 265,000 shares of the biotechnology company’s stock worth $890,000 after buying an additional 32,000 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Brainstorm Cell Therapeutics by 27.5% during the 1st quarter. JPMorgan Chase & Co. now owns 246,202 shares of the biotechnology company’s stock worth $827,000 after buying an additional 53,036 shares in the last quarter. State Street Corp boosted its holdings in shares of Brainstorm Cell Therapeutics by 10.8% during the 1st quarter. State Street Corp now owns 96,060 shares of the biotechnology company’s stock worth $323,000 after buying an additional 9,357 shares in the last quarter. S.C. Financial Services Inc. boosted its holdings in shares of Brainstorm Cell Therapeutics by 66.6% during the 2nd quarter. S.C. Financial Services Inc. now owns 25,471 shares of the biotechnology company’s stock worth $70,000 after buying an additional 10,186 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Brainstorm Cell Therapeutics during the 2nd quarter worth approximately $57,000. Institutional investors and hedge funds own 10.83% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

(Get Rating)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

See Also

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.